Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ivacaftor in children aged 3-5 with a CFTR gating mutation in cystic fibrosis has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2018-11-19